ROCURONIUM BROMIDE INJECTION 10 MG
ROCURONIUM BROMIDE : 10 MG · DIN 02318121 · PFIZER CANADA ULC
Health Canada status: CANCELLED POST MARKET
What is ROCURONIUM BROMIDE INJECTION?
ROCURONIUM BROMIDE INJECTION 10 MG contains ROCURONIUM BROMIDE : 10 MG. It is listed in the Health Canada Drug Product Database under DIN 02318121, held by PFIZER CANADA ULC, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as cancelled post market, status dated 16-Jan-2026. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ROCURONIUM BROMIDE INJECTION used for?
Adjunct to general anesthesia to facilitate routine or rapid sequence endotracheal intubation and provide skeletal muscle relaxation during surgery or mechanical ventilation.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02318121 |
|---|---|
| Brand name | ROCURONIUM BROMIDE INJECTION |
| Generic / active ingredient | ROCURONIUM BROMIDE : 10 MG |
| Manufacturer | PFIZER CANADA ULC |
| Strength | 10 MG |
| Dosage form | SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Prescription |
| ATC code | M03AC09 ROCURONIUM BROMIDE |
| AHFS class | 12:20.20 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 16-Jan-2026 |
| Original market date | 2009-02-10 00:00:00 |
How is it administered?
Administer IV only. Routine intubation: 0.6 mg/kg. Rapid sequence: 0.6-1.0 mg/kg. Maintenance: 0.15 mg/kg. Continuous infusion: 0.3-0.6 mg/kg/h. Dosage must be individualized.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store at 2°C to 8°C. (Note: General practice for rocuronium, though specific text snippet ends before storage details).
How is it supplied?
5 mL vials.
Contraindications
Hypersensitivity to rocuronium bromide, any ingredient in the formulation, or component of the container.
Warnings and precautions
Must be administered by experienced clinicians. Risk of respiratory paralysis; ventilatory support mandatory. Risk of death due to medication errors (paralysis). Monitor for anaphylaxis.
Is ROCURONIUM BROMIDE in shortage in Canada?
A Canadian shortage report is on file for this molecule: Active — reported by JUNO PHARMA CANADA INC., last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code M03AC09 ROCURONIUM BROMIDE. 6 of 12 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ROCURONIUM BROMIDE INJECTION | 10 MG | SOLUTION | AURO PHARMA INC | MARKETED | DIN 02498820 |
| ROCURONIUM BROMIDE INJECTION | 10 MG | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02318415 |
| ROCURONIUM BROMIDE INJECTION | 10 MG | SOLUTION | JAMP PHARMA CORPORATION | MARKETED | DIN 02529831 |
| ROCURONIUM BROMIDE INJECTION | 10 MG | SOLUTION | EUGIA PHARMA INC. | MARKETED | DIN 02528657 |
| ROCURONIUM BROMIDE INJECTION | 10 MG | SOLUTION | HIKMA CANADA LIMITED | MARKETED | DIN 02517744 |
| ROCURONIUM BROMIDE INJECTION | 10 MG | SOLUTION | JUNO PHARMACEUTICALS CORP. | MARKETED | DIN 02469774 |
| INJECTABLE ROCURONIUM BROMIDE | 10 MG | SOLUTION | OMEGA LABORATORIES LIMITED | CANCELLED PRE MARKET | DIN 02539489 |
| ROCURONIUM BROMIDE INJECTION | 10 MG | SOLUTION | STERIMAX INC | APPROVED | DIN 02442752 |
| ROCURONIUM BROMIDE INJECTION | 10 MG | SOLUTION | OMEGA LABORATORIES LIMITED | CANCELLED POST MARKET | DIN 02382415 |
| ROCURONIUM BROMIDE INJECTION SDZ | 10 MG | SOLUTION | SANDOZ CANADA INCORPORATED | CANCELLED PRE MARKET | DIN 02390566 |
Who else supplies ROCURONIUM BROMIDE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. ROCURONIUM BROMIDE appears in 31 registered pack listings across 5 markets, published on 4 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.